Guidelines or guidance for better idiopathic pulmonary fibrosis management?

BMC Medicine

Volumn 14, Issue 1, 2016, Pages

  Behr, Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Evidence based medicine; GRADE; Guidelines; Idiopathic pulmonary fibrosis

Indexed keywords

NINTEDANIB; PIRFENIDONE;

CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMORBIDITY; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG INDUSTRY; EDITORIAL; EVIDENCE BASED MEDICINE; FIBROSING ALVEOLITIS; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; MEDICAL DECISION MAKING; MEDICAL PRACTICE; PATIENT CARE; PRACTICE GUIDELINE; QUALITY CONTROL; IDIOPATHIC PULMONARY FIBROSIS; PULMONOLOGY; STANDARDS;

EVIDENCE-BASED MEDICINE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PRACTICE GUIDELINES AS TOPIC; PULMONARY MEDICINE;

EID: 84957568622     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-016-0567-9     Document Type: Editorial

References (10)

1. Greenhalgh T, Howick J, Maskrey N, Evidence Based Medicine Renaissance Group. Evidence based medicine: a movement in crisis? BMJ. 2014;348:g3725. doi: 10.1136/bmj.g3725.
2. Wells AU. The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF)--practical implications. Respir Res. 2013;14 Suppl 1:S2. doi: 10.1186/1465-9921-14-S1-S2.
3. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
4. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-6.
5. Wells AU. Managing diagnostic procedures in idiopathic pulmonary fibrosis. Eur Respir Rev. 2013;22(128):158-62.
6. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. ATS, ERS, JRS, and ALAT. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192(2):e3-e19. doi: 10.1164/rccm.201506-1063ST.
7. Rochwerg B, Schünemann H, Raghu G. Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach. BMC Med. 2016. doi: 10.1186/s12916-016-0563-0.
8. Wells AU. Any fool can make a rule and any fool will mind it. BMC Med. 2016. doi: 10.1186/s12916-016-0562-1.
9. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-82.
10. King Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-92.